Global

A new campaign in France hopes to build on the nation’s legacy as a life sciences innovator, through championing a fresh pathway to success in areas such as preventative healthcare, advanced diagnostics, medical devices, home care, and big data.

Envigo's new CEO shares with Pharm Exec his vision for the company’s future, the changes he’s seen in the industry, and his thoughts on that thorny subject, Brexit.

Reflector outlines the obstacles ahead for Europe's revamped Innovative Medicines Initiative.

If managed access is to be a widely available option, it makes sense to re-think just how much should be spent on it, writes Leela Barham.

Although Hungary has posted the third-highest economic growth rate in the EU since 2014, its healthcare system is struggling-dictating the need for new efforts if the country is to regain its dominance as a central and eastern European-region trailblazer in the life sciences.

Paul Ranson examines how the UK biopharma must now adapt to a changing landscape.

Leela Barham reports on the latest evolution of the CDF.

Leela Barham looks at the EU plans for a European patent, and asks where the UK will fit in after Brexit.

Not yet, says Reflector. But to judge from the European Parliament's latest foray into the subject, there could be plenty of support for such an approach to this complicated subject.

A look at how Europe's new accelerated drug approval scheme can evolve existing review pathways for the better-and take a page from FDA

The long planned for transparency of industry payments to doctors, pharmacists, nurses and others has shone some dappled light on the UK industry, writes Leela Barham.

Dave Handelsman offers a smart approach to dealing with the EMA's new guidelines on the anonymization of clinical trial data.

The UK's Brexit vote has unleashed turbulence in Europe - not least on its pharma sector. Reflector reports.

Leela Barham looks at the implications for the UK industry in the aftermath of last week's vote for Brexit.

Only one polling company correctly predicted the UK's Brexit outcome. Graeme Hutton reports.

The UK vote suddenly puts industry on a turbulent track in Europe. The many challenges and effects are outlined here.

With one of the oldest populations in the world, Italy faces a daunting question: how can it protect its universal healthcare system while maintaining the country’s high quality standards for public healthcare and ensuring its survival for the next generation? Up to the challenge, Italy must now learn to do more with less.

Companies that want to tap into the full potential of Asia-Pac must boost the role of their regional headquarters.

EU and UK industry groups did their best to display calm and confidence as the world woke up to the reality of Brexit.

A new industry working group explores alternative drug funding options in Europe-and asks key stakeholders in the region to join the discussion.

Do recent trends in the pharma and biotech M&A and equity markets signal a temporary lull - or a permanent drop? Peter Young reports.

Radicals who wield real power at the EMA have gone public with their thinking about the role of regulators in the economic aspects of medicines provision – despite the decades-old EU taboo about linking pricing with authorizations.

NHS England head Simon Stevens believes the UK's PPRS needs significantly updating.

Eleanor Biggs looks at the biggest uncertainties facing the pharma industry if the UK were to leave the EU.

While the Italian fashion and automotive industries may steal the global thunder, another sector in Italy flourishes beneath the public’s radar. The country’s pharmaceutical industry continues to punche above its weight in many areas and has supported Italy’s national economy through many periods of weakness.

We desperately need new anti-infective drugs to avoid life threatening infections. Let’s make that happen by punishing companies who don’t invest in R&D for these specific drugs.

Is a more "light-touch" appraisal process the key to getting the UK's NICE to do more with less? Leela Barham reports.

European pharma is bracing itself for EFPIA’s June deadline requiring the disclosure of transfer-of-value transactions make to HCPs. Pharm Exec looks at how the industry is preparing for this historic moment.

The dilemma continues: Which medicines should Europe's health systems pay for – and how much should they pay?

As companies look to raise capital, selling and then leasing back real estate is a tempting option and one that other industries are utilizing, writes Karen Williamson.